.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
GENEVA The World Health Organization gave emergency use authorization Friday to a COVID-19 vaccine manufactured by China s Sinopharm, potentially paving the way for millions of the doses to reach needy countries through a U.N.-backed program rolling out coronavirus vaccines. The decision by a WHO technical advisory group, a first for a Chinese vaccine, opens the possibility that Sinopharm s offering could be included in the U.N.-backed COVAX program in coming weeks or months and distributed through U.N. children s agency UNICEF and WHO s Americas regional office. Aside from efficacy numbers, the Chinese manufacturer has released very little public data about its two vaccines one developed by its Beijing Institute of Biological Products and the other by the Wuhan Institute of Biological Products.
.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.
.The Sinopharm vaccine will join ones made by Pfizer-BioNTech, Johnson & Johnson, Moderna, AstraZeneca, and a version of the AstraZeneca vaccine made by the Serum Institute of India, in receiving the coveted authorization from the U.N. health agency.
“This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine,” Tedros said at a Geneva news conference.
Previously, a separate group advising WHO on vaccines said it was “very confident” the Sinopharm vaccine protects people ages 18-59. The group said it had a “low level of confidence” in the vaccine s efficacy for people 60 and over. Its members said they had “very low confidence” in the available data about serious side effects in that age group.